All News

After a challenging year due to COVID-19 and rising blood test numbers, a woman living with ovarian cancer shares on what she’s learned and how she’s approaching 2022.

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

The recent FDA approval of Keytruda, an immunotherapy monoclonal antibody drug, for children with melanoma is an exciting development, according to an expert. But there is potential for certain side effects that children and their family should consider before undergoing treatment.

From long-term effects of pediatric cancer to a survivor fulfilling her dream of being an astronaut, CURE® looked back on its most-read childhood cancer stories of the year.

A sister of a woman with cancer writes about how the idea of recurrence faded to the back of her mind, but now she must be realistic about the future.

The Food and Drug Administration will offer guidance and expedited review to CLN-081, a novel drug that is promising for the treatment of EGFR exon 20-mutated non-small cell lung cancer.

From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.

Patients with Down syndrome have an increased risk for leukemia during childhood, and toxicities related to treatment may be more common in this patient population.

A cancer survivor pens a poem about his New Year’s resolutions to help other survivors through obstacles in 2022.

Patients with a common brain tumor subtype that expresses ERK1/2 activation may obtain a greater survival benefit with PD-1 immunotherapy, although research needs to confirm whether this can be observed in all patients.

An oncologist from Fox Chase Cancer Center in Philadelphia explains the early career mentorship that inspired his successful lung cancer career.

Not having known much about lung cancer, a woman describes her shock at receiving a diagnosis despite being a non-smoker.

CURE® compiled its top 5 most-listened-to podcast episodes from this year, featuring cancer survivor stories, caregivers and experts.

A lung cancer doctor explains how he got lucky to fill in a role in the lung cancer space, and his career and passion took off from there.

A woman who has worked with Upal Basu Roy in the lung cancer space for many years explains why he is a lung cancer hero to everyone he has worked with, due to his dedication and empathy.

A young adult cancer survivor describes the ways people typically misunderstand his cancer experiences.

As the standard treatment for patients with renal cell carcinoma, the most common type of kidney cancer, related to VHL disease is often surgical procedures, the use of Welireg may reduce surgical burden in patients.

From nurse navigators to surgeons, clinical social workers and more, a patient with cancer often has a village of team members helping them achieve a smooth and successful treatment experience.

A person with cancer may naturally assume an oncologist will follow them throughout the course of treatment, but when that person survives for many years, things can rapidly change.

A lung cancer survivor describes a passionate advocate who has changed the world of many patients.

Children with low skeletal muscle density were more likely to have hematologic toxicities from chemotherapy, but more research is needed to determine whether this measure is an accurate predictor of chemotoxicities in lymphoma.

From celebrity deaths to exciting new treatments, here is CURE®’s roundup of what made waves in the brain cancer space this year.

A cancer survivor discusses the hurtful words people say to cancer survivors and why they sting.

A man writes about how his wife’s doctor saved her life after she was given three weeks to three months to live.

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.

2021 was full of research advancements and FDA drug approvals that continue to improve cancer care for patients with a variety of malignancies.

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

A colleague describes Dr. Edward S. Kim’s devotion to improving lung cancer care and creating more inclusive clinical trial practices.

The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.